TheraRadar
Clinical-Stage Companies / JCR Pharmaceuticals

JCR Pharmaceuticals

Pre-Approval PRO BETA
12
Total Trials
4
Phase 3
10
Phase 2
5
Recruiting
163
Score

Pipeline by Phase

Phase 3
4
Phase 2
10
Phase 1
6

Therapeutic Focus

Mucopolysaccharidosis II Mucopolysaccharidosis I Mucopolysaccharidosis III-B Mucopolysaccharidosis III-A Mucopolysaccharidosis IIIB

Clinical Trials (12)

NCT04573023 Phase 3 ACTIVE NOT RECRUITING

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Started: 2/14/2022

NCT05594992 Phase 3 ENROLLING BY INVITATION

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

Started: 2/22/2023

NCT04348136 Phase 2 ACTIVE NOT RECRUITING

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Started: 9/1/2019

NCT03708965 Phase 2 ACTIVE NOT RECRUITING

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Started: 1/1/2019

NCT03359213 Phase 2 COMPLETED

A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)

Started: 7/26/2018

NCT03568175 Phase 2 COMPLETED

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Started: 8/1/2018

NCT06488924 Phase 1 RECRUITING

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Started: 11/5/2024

NCT04453085 Phase 1 COMPLETED

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Started: 10/28/2021

NCT06095388 Phase 1 ACTIVE NOT RECRUITING

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Started: 10/4/2023

NCT04227600 Phase 1 COMPLETED

A Study of JR-171 in Patients With Mucopolysaccharidosis I

Started: 9/1/2020

NCT03128593 Phase 1 COMPLETED

A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Started: 3/30/2017

NCT07640984 Phase 1 NOT YET RECRUITING

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Started: 6/18/2026

Drug Candidates

JR-141 Idursulfase JR-141 or Idursulfase JR-446 JR-171 JR-441 JR-171 (lepunafusp alfa)
Activity Status: Active
Last Trial Started: 6/18/2026
Last Trial Ended: 5/2/2025
Trials (12 months): 1
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.